Drugs / TN-201
TN-201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05836259 | Aug 2023 → Aug 2027 expected | hypertrophic cardiomyopathy | Tenaya Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TN-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05836259 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “recombinant adeno-associated virus serotype 9 (AAV9)” NCT05836259 ↗ |
| Route | Intravenous | “intravenous dose” NCT05836259 ↗ |
| Target | MYBPC3 | “Myosin Binding Protein C (MYBPC3) transgene” NCT05836259 ↗ |